H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

H.C. Wainwright downgraded Juniper Pharmaceuticals (NASDAQ: JNP) from Buy to Neutral with a price target of $6.75. Analyst Ed Arce noted that after markets closed on August 17, Juniper announced in a terse release that the Phase 2b trial of its lead drug candidate, COL-1077 (10% lidocaine bioadhesive gel), failed to achieve its primary and secondary endpoints, and that based on these results, the company is discontinuing development of the product.

For an analyst ratings summary and ratings history on Juniper Pharmaceuticals click here. For more ratings news on Juniper Pharmaceuticals click here.

Shares of Juniper Pharmaceuticals closed at $5.75 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Merck (MRK) PT Raised to $143 at Truist Securities
• Amazon.com (AMZN) PT Raised to $215 at UBS